Monographie - Mitomycin

Letztes “update” :
19/11/2024

Mitomycin

Chemische Struktur

Handelsmarke

Handelsnamen sind als beispielhaft anzusehen. Sonstige Bestandteile können je nach Hersteller oder Land verschieden sein

Ametycine	Frankreich
Crisofimina	Argentinien
Fatrix	Chile
Maximitom	Argentinien
Maximiton	Ecuador
Minazol	Kolumbien
Mitameta	Italien
Mitem	Deutschland, Schweiz
Mitocin	Brasilien
Mitokebir	Argentinien, Ecuador
Mitolem	Kolumbien, Venezuela
Mitomicina	Argentinien, Chile, Ecuador, Italien, Mexiko, Peru, Portugal, Rumänien, Spanien
Mitomycin	Belgien, Dänemark, Deutschland, Finnland, Griechenland, Großbritannien, Iran, Irland, Italien, Malaysia, Neuseeland, Norwegen, Österreich, Polen, Schweden, Slowenien, Türkei, Ungarn, Vereinigte Staaten von Amerika
Mitomycine	Luxemburg, Niederlande
Mitotie	Argentinien, Chile, Ecuador, Peru
Mitozytrex	Vereinigte Staaten von Amerika
Mixandex	Kolumbien, Mexiko
Mutamycin	Vereinigte Staaten von Amerika
Riptam	Kolumbien
Ronzine	Argentinien, Peru
Urocin	Deutschland

Literaturverzeichnis : Mitomycin

	Typ	Veröffentlichung
3	Zeitung	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81	Zeitung	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Zeitung	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Zeitung	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Zeitung	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Zeitung	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Zeitung	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Zeitung	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307	Zeitung	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Zeitung	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Zeitung	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
407	Zeitung	Quebberman EJ, Hoffman NE, Ausman RK, Hamid AAR. Stability of mitomycin admixtures. Am J Hosp Pharm 1985 ; 42: 1750-1754.
485	Zeitung	Dorr RT, Liddil JD. Stability of mitomycin C in different infusion fluids: compatibility with heparin and glucocorticosteroids. J Oncol Pharm Practice 1995 ; 1: 19-24.
648	Zeitung	Das Gupta V. Stability of mitomycin aqueous solution when stored in tuberculin syringes. Int J Pharm Compound 1997 ; 1: 282-283.
835	Zeitung	Edwards D, Selkirk AB, Taylor RB. Determination of the stability of mitomycin C by high performance liquid chromatography. Int J Pharm 1979 ; 4: 21-26.
905	Zeitung	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1026	Zeitung	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1178	Zeitung	Benvenuto JA, Anderson RW, Kerkof K, Smith RG, Loo TL. Stability and compatibility of antitumor agents in glass and plastic containers. Am J Hosp Pharm 1981 ; 38: 1914-1918.
1239	Zeitung	Stolk LML, Fruijtier A, Umans. Stability after freezing and thawing of solutions of mitomycin C in plastic minibags for intravesical use. Pharm Weekbl [Sci] 1986 ; 8: 286-288.
1410	Zeitung	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	Zeitung	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1827	Zeitung	Beijnen JH, Van Gijn R, Underberg WJM. Chemical stability of the antitumor mitomycin C in solutions for intravesical instillation. J Parenter Sci Technol 1990 ; 44: 332-335.
2247	Zeitung	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3128	Labor	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3575	Labor	Mitomycine (Ametycine®) - Résumé des caractéristiques du produit Prostrakan 2013
3897	Zeitung	Briot T, Truffaut C, Le Quay L, Lebreton A, Lagarce F. Stability of Reconstituted and Diluted Mitomycin C Solutions in Polypropylene Syringes and Glass Vials. Pharmaceutical Technology in Hospital Pharmacy 2016 ;1,2:83-89
4154	Labor	Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018
4282	Zeitung	Myers A-L, Zhang Y-P, Kawedia J-D, Zhou X,. Sobocinski S-M, Metcalfe M-J, Kramer M-A, Dinney C.P.N, Kamat A-M. Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration. Drugs R D 2017
4367	Zeitung	Kinast R.M, Akula K.K, DeBarber A.E, Barker G.T, Gardiner S.K, Whitson E, Mansberger S.L. The Degradation of Mitomycin C Under Various Storage Methods. J Glaucoma 2016 ; 25, 6: 477-481.
4471	Labor	Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 Kyowa Kirin Pharma 2019
4526	Zeitung	Nisse, Y.E, Vigneron J, Zenier H, D'Huart E, Demoré B. Stability of mitomycin in polypropylene syringes for use in glaucoma surgery. EJOP 2021 4: 1.
4763	Zeitung	Almasi J, Erdnuss F, Thiesen J, Krämer I. Physicochemical stability of urea-containing Mitomycin C preparations in glass vials (1.0 mg/mL) and plastic syringes (2.0, 0.4, 0.2 mg/mL) Pharmaceutical Technology in Hospital Pharmacy 2023 ;8,1

Mentions Légales